Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07737314

Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study

This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location contact

Nicole Dussault, MD, MS

PRINCIPAL_INVESTIGATOR

Sheri Ballard

CONTACT

[email protected]

206-667-4222

About this study

OUTLINE:

Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.

After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
  • A cancer diagnosis
  • Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
  • Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
  • Ability to understand and willingness to agree to an electronic consent document
  • Enrolled in MyChart and ability to participate in a telehealth video visit

Exclusion criteria

  • Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages

Treatment and study plan

Survey Administration

Other

Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability

Electronic Health Record Review

Other

Ancillary studies

Primary outcomes

  1. Percentage of referred patients who attend pharmacist education session (Feasibility)

    Time frame: Up to 6 months

    Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.

  2. Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire

    Time frame: Up to 1 month post-session

    Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as > 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.

Study contacts

Contact information is provided by the study sponsor or research team.

Sheri Ballard

CONTACT

[email protected]

206-667-4222

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 30, 2026
Registry last updated
Jul 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.